Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17282907 | 0.88 | GAA (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14234456 | 0.88 | GAA (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14234967 | 0.88 | GAA (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL25985625 | 0.87 | HDAC3 (0.32) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17283055 | 0.85 | CA12 (0.34) | PDE4B | |
| SCHEMBL23446821 | 0.84 | GAA (0.34) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15723423 | 0.84 | HDAC3 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23447588 | 0.84 | GAA (0.34) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15259060 | 0.83 | PDE4B (0.35) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL26477159 | 0.82 | CTSD (0.34) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200262869-A1 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF | GENENTECH, INC. | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262869-A1 | PEPTIDE ANTIBIOTIC COMPLEXES AND METHODS OF USE THEREOF | SPAST, PEPD, DNPEP | HDAC3 2382/4885HDAC4 2833/4885HDAC1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.